Small cell cancer of the bladder: Pathology, diagnosis, treatment and prognosis

Bulletin du Cancer

Volumn 96, Issue 6, 2009, Pages

  Ismaili, N ^a,b   Arifi, S ^c,d   Flechon, A ^b   El Mesbahi, O ^c   Blay, J Y ^d   Droz, J P ^b   Errihani, H ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

^b CENTRE LÉON BÉRARD   (France)

^c HASSAN II UNIVERSITY HOSPITAL   (Morocco)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bladder cancer; Rare tumour and small cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN; VINBLASTINE; VINCRISTINE; TUMOR MARKER;

ADJUVANT THERAPY; AGE DISTRIBUTION; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; BLADDER SURGERY; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CLINICAL FEATURE; CYSTECTOMY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATURIA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MICROSCOPY; MOLECULAR GENETICS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPOTENT STEM CELL; NEUROENDOCRINE TUMOR; PATHOGENESIS; PROGNOSIS; REVIEW; SEX DIFFERENCE; SMALL CELL CARCINOMA; TRANSURETHRAL RESECTION; BLADDER TUMOR; METHODOLOGY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; HEMATURIA; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 67651049789     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0883     Document Type: Review

References (70)

1. Bone RC, Deer D. Oat cell carcinoma of the larynx. Laryngoscope 1978; 88: 1190-1195
2. Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer 2004; 90: 1720-1726 (Pubitemid 38725641)
3. Huntsman DG, Clement PB, Gilks CB, Scully RE. Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. Am J Surg Pathol 1994; 18: 364-375 (Pubitemid 24093601)
4. Francois A, Chatikhine VA, Chevallier B, Ren GS, Berry M, Chevrier A, et al. Neuroendocrine primary small cell carcinoma of the breast. Report of a case and review of the literature. Am J Clin Oncol 1995; 18: 133-138
5. Delaloge S, Pautier P, Kerbrat P, Castaigne D, Haie-Meder C, Duvillard P, et al. Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature. Clin Oncol 2000; 12: 357-362 (Pubitemid 32051520)
6. Mackey JR, Au HJ, Hugh J, Venner P. Genito-urinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. J Urol 1998; 159: 1624-1629 (Pubitemid 29117354)
7. Blomjous CEM, Vos W, De Voogt HJ, van der Valk P, Meijer CJLM. Small cell carcinoma of the urinary bladder. A clinicopathologic, morphologic, immunohistochemical and ultrastructural study of 18 cases. Cancer 1989; 64 (6): 1347-1357
8. Holmang S, Borghede G, Johansson SL. Primary small cell carcinoma of the bladder: a report of 25 cases. J Urol 1995; 153 (6): 1820-1822
9. Lohrisch C, Murray N, Pickles T, Sullivan L. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer 1999; 86 (11): 2346-2352 (Pubitemid 30010377)
10. Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005; 103 (6): 1172-1178
11. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern California experience. J Urol 2005; 174 (1): 93-96 (Pubitemid 40825681)
12. Ismaili N, Elkarak F, Heudel PE, Flechon A, Droz JP. Small cell cancer of the bladder: the Leon-Berard Cancer Centre experience. Indian J Urol 2008; 24: 494-497
13. Cramer SF, Aikawa M, Cebelin M. Neurosecretory granules in small cell invasive carcinoma of the urinary bladder. Cancer 1981; 47 (4): 724-730 (Pubitemid 11135870)
14. Grignon DJ, Ro JY, Ayala AG, Shum DT, Ordóñez NG, Logothetis CJ, et al. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. Cancer 1992; 69 (2): 527-536
15. Iczkowski KA, Shanks JH, Allsbrook WC, Lopez-Beltran A, Pantazis CG, Collins TR, et al. Small cell carcinoma of urinary bladder is differentiated from urothelial carcinoma by chromogranin expression, absence of CD44 variant 6 expression, a unique pattern of cytokeratin expression, and more intense gamma-enolase expression. Histopathology 1999; 35 (2): 150-156 (Pubitemid 29378515)
16. Trias I, Algaba F, Condom E, Español I, Seguí J, Orsola I, et al. Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur Urol 2001; 39 (1): 85-90.
17. Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 2004; 101 (5): 957-962 (Pubitemid 39100428)
18. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M.D. Anderson cancer experience. J Urol 2004; 172 (2): 481-484 (Pubitemid 38900183)
19. Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 2005; 46 (1): 57-63. (Pubitemid 40193699)
20. Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, van Boven H, Meinhardt W, et al. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology 2005; 65 (2): 295-299 (Pubitemid 40248016)
21. Mukesh M, Cook N, Hollingdale AE, Ainsworth NL, Russell SG. Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. BJU Int 2009; 13 (6): 747-752
22. Ali SZ, Reuter VE, Zakowski MF. Small cell neuroendocrine carcinoma of the urinary bladder: a clinicopathologic study with emphasis on cytologic features. Cancer 1997; 79: 356-361 (Pubitemid 27029900)
23. Oesterling JE, Brendler CB, Burgers JK, Marshall FF, Epstein JI. Advanced small cell carcinoma of the bladder. Successful treatment with combined radical cystoprostatectomy and adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1990; 65 (9): 1928-1936
24. Bacon C. Chemotherapy for bladder cancer. In: Waxman J, ed. Urological cancers. London: Springer, 2005: 145-155
25. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22 (12): 1435-1448 (Pubitemid 28550639)
26. Mangar SA, Logue JP, Shanks JH, Cooper RA, Cowan RA, Wylie JP. Small-cell carcinoma of the urinary bladder: 10-year experience. Clin Oncol (R Coll Radiol) 2004; 16 (8): 523-527 (Pubitemid 39517659)
27. Bex A, de Vries R, Pos F, Kerst M, Horenblas S. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J Urol 2009; 27 (1): 101-106 [Epub 2008 Jul 8].
28. Reyes CV, Soneru I. Small cell carcinoma of the urinary bladder with hypercalcemia. Cancer 1985; 56 (10): 2530-2533 (Pubitemid 16202455)
29. Sved P, Gomez P, Manoharan M, Civantos F, Soloway MS. Small cell carcinoma of the bladder. BJU Int 2004; 94 (1): 12-17
30. Jones TD, Kernek KM, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, et al. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol 2005; 36 (7): 718-723 (Pubitemid 41112025)
31. Wang X, Zhang S, MacLennan GT, Eble JN, Lopez-Beltran A, Yang XJ, et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 2007; 13 (3): 953-957 (Pubitemid 46340372)
32. Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, Koch MO, et al. C-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol 2005; 18 (3): 320-323 (Pubitemid 40395348)
33. Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 2000; 13 (3): 238-242 (Pubitemid 30207508)
34. Terracciano L, Richter J, Tornillo L, Beffa L, Diener PA, Maurer R, et al. Chromosomal imbalances in small cell carcinomas of the urinary bladder. J Pathol 1999; 189 (2): 230-235 (Pubitemid 29448918)
35. Léonard C, Huret JL, GFCO; Groupe français de cytogénétique oncologique. From cytogenetics to cytogenomics of bladder cancers. Bull Cancer 2002; 89 (2): 166-173
36. Church DN, Bahl A. Clinical review: small cell carcinoma of the bladder. Cancer Treat Rev 2006; 32 (8): 588-593 [Epub 2006 sep 27]. (Pubitemid 44752562)
37. Christopher ME, Seftel AD, Sorenson K, Resnick MI. Small cell carcinoma of the genitourinary tract: an immunohistochemical, electron microscopic and clinicopathological study. J Urol 1991; 146 (2): 382-388
38. van Hoeven KH, Artymyshyn RL. Cytology of small cell carcinoma of the urinary bladder. Diagn Cytopathol 1996; 14 (4): 292-297 (Pubitemid 26177675)
39. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990; 322 (16): 1129-1138
40. Pan CX, Zhang H, Lara Jr. PN, Cheng L. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther 2006; 6 (12): 1707-1713 (Pubitemid 46062305)
41. Puente S, Velasco A, Gallel P, Pallares J, Perez-Ruiz L, Ros S, et al. Metastatic small cell carcinoma to the thyroid gland: a pathologic and molecular study demonstrating the origin in the urinary bladder. Endocr Pathol 2008; 19 (3): 190-196
42. Chin Jr. R, McCain TW, Miller AA, Dunagan DP, Acostamadiedo J, Douglas CL, et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 2002; 37: 1-6. (Pubitemid 34621450)
43. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004; 22: 3248-3254 (Pubitemid 41103679)
44. Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31: 1614-1620 (Pubitemid 40104607)
45. Bastús R, Caballero JM, González G, Borrat P, Casalots J, Gomez de Segura G, et al. Small cell carcinoma of the urinary bladder treated with chemotherapy and radiotherapy: results in five cases. Eur Urol 1999; 35 (4): 323-326 (Pubitemid 29154839)
46. Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 2009; 27 (1): 3-7.
47. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, et al. Randomized comparison of etoposidecisplatin versus etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5 (7): 601-607 (Pubitemid 24283096)
48. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005; 366 (9494): 1385-1396
49. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83 (12): 855-861
50. Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, et al. Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20 (24): 4665-4672 (Pubitemid 36025283)
51. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10 (2): 282-291
52. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346 (2): 85-91. (Pubitemid 34438898)
53. Hanna N, Bunn Jr. PA, Langer C, Einhorn L, Guthrie Jr. T, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24 (13): 2038-2043 (Pubitemid 46622112)
54. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658-667 (Pubitemid 29075255)
55. von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19 (6): 1743-1749 (Pubitemid 32230876)
56. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25 (15): 2086-2092 (Pubitemid 46972795)
57. Ardizzoni A, Manegold C, Debruyne C, Gaafar R, Buchholz E, Smit EF, et al. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 2003; 9 (1): 143-150 (Pubitemid 36109726)
58. Banham S, Soukop M, Burnett A, Stevenson R, Cunningham D, Tansey P, et al. Treatment of small cell carcinoma of lung with late dosage intensification programmes containing cyclophosphamide and mesna. Cancer Treat Rev 1983; 10 (Suppl A): 73-77 (Pubitemid 14249401)
59. Smith IE, Evans BD, Harland SJ, Robinson BA, Yarnold JR, Glees JG, et al. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma. Cancer Chemother Pharmacol 1985; 14: 120-124 (Pubitemid 15164811)
60. Cunningham D, Banham SW, Hutcheon AH, Dorward A, Ahmedzai S, Tansey P, et al. High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung. Cancer Chemother Pharmacol 1985; 15: 303-306 (Pubitemid 15240984)
61. Spitzer G, Farha P, Valdivieso M, Dicke K, Zander A, Vellekoop L, et al. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol 1986; 4: 4-13. (Pubitemid 16155955)
62. Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, Machiels J, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5: 1864-1873 (Pubitemid 18010145)
63. Souhami RL, Hajichristou HT, Miles DW, Earl HM, Harper PG, Ash CM, et al. Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer. Cancer Chemother Pharmacol 1989; 24: 321-325 (Pubitemid 19202958)
64. Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995; 13 (1): 148-156
65. Elias AJ, Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 1999; 17: 1175. (Pubitemid 29162941)
66. Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, et al. Standard and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. Ann Oncol 1999; 10: 561-567 (Pubitemid 29305434)
67. Humblet Y, Bosquee L, Weynants P, Symann M. High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells. Bone Marrow Transplant 1996; 18: S36-9. (Pubitemid 126754143)
68. Leyvraz S, Ketterer N, Perey L, Bauer J, Vuichard P, Grob JP, et al. Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor. Br J Cancer 1995; 72: 178-182
69. Leyvraz S, Perey L, Rosti G, Lange A, Pampallona S, Peters R, et al. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999; 17: 3531-3539 (Pubitemid 29517924)
70. Elias AD, Skarin AT, Richardson P, Ibrahim J, McCauley M, Frei 3rd E. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. Biol Blood Marrow Transplant 2002; 8 (6): 326-333